These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2484685)

  • 41. Clinical comparison of nitrates and sydnonimines.
    Rudolph W; Dirschinger J
    Eur Heart J; 1991 Nov; 12 Suppl E():33-41. PubMed ID: 1790782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of the active metabolite of molsidomine in human plasma by reversed-phase high-performance liquid chromatography.
    Dutot C; Moreau J; Cordonnier P; Spreux-Varoquaux O; Klein C; Ostrowski J; Advenier C; Gärtner W; Pays M
    J Chromatogr; 1990 Jun; 528(2):435-46. PubMed ID: 2384581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
    Spreux-Varoquaux O; Ulmer B; Cordonnier P; Forestier A; Pays M; Ducreuzet C; Advenier C
    Fundam Clin Pharmacol; 1991; 5(6):549-56. PubMed ID: 1955198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oxidative/Nitrative Mechanism of Molsidomine Mitotoxicity Assayed by the Cytochrome c Reaction with SIN-1 in Models of Biological Membranes.
    Paes de Barros M; Casares Araujo-Chaves J; Marlise Mendes Brito A; Lourenço Nantes-Cardoso I
    Chem Res Toxicol; 2020 Nov; 33(11):2775-2784. PubMed ID: 32706246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Release of plasminogen activator by SIN-1].
    Kloecking HP; Hoffmann A; Markwardt F
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):231-2. PubMed ID: 3104866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stability behaviour of molsidomine-containing pellet formulations.
    Laicher A; Jünger H; Klemm FH
    J Pharm Pharmacol; 1997 Feb; 49(2):131-4. PubMed ID: 9055182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamics of Irreversible NO Release from Photoexcited Molsidomine.
    Yoon H; Park S; Lim M
    J Phys Chem Lett; 2023 Jan; 14(2):516-523. PubMed ID: 36626829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decomposition mechanism of 3-N-morpholinosydnonimine (SIN-1)--a density functional study on intrinsic structures and reactivities.
    Rojas Wahl RU
    J Mol Model; 2004 Apr; 10(2):121-9. PubMed ID: 14997366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New aspects of the mechanism of action of molsidomine. Proceedings of a discussion by cardiology experts. Berlin, 15 April 1989].
    Med Klin (Munich); 1990 Feb; 85 Suppl 1():3-26. PubMed ID: 2333059
    [No Abstract]   [Full Text] [Related]  

  • 50. The design of membrane-controlled transdermal therapeutic systems containing molsidomine.
    Yamada M; Tanigawara Y
    Chem Pharm Bull (Tokyo); 1987 Aug; 35(8):3407-12. PubMed ID: 3427719
    [No Abstract]   [Full Text] [Related]  

  • 51. Nitric Oxide as a Central Molecule in Hypertension: Focus on the Vasorelaxant Activity of New Nitric Oxide Donors.
    da Silva GM; da Silva MC; Nascimento DVG; Lima Silva EM; Gouvêa FFF; de França Lopes LG; Araújo AV; Ferraz Pereira KN; de Queiroz TM
    Biology (Basel); 2021 Oct; 10(10):. PubMed ID: 34681140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sex and death: the effects of innate immune factors on the sexual reproduction of malaria parasites.
    Ramiro RS; Alpedrinha J; Carter L; Gardner A; Reece SE
    PLoS Pathog; 2011 Mar; 7(3):e1001309. PubMed ID: 21408620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of molsidomine on hypoxia inducible factor alpha and Sonic hedgehog in testicular ischemia/reperfusion injury in rats.
    Dokucu AI; Ozturk H; Ozturk H; Tuncer MC; Yilmaz F
    Int Urol Nephrol; 2009; 41(1):101-8. PubMed ID: 18787973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro studies of interactions of NO. donor drugs with superoxide and hydroxyl radicals.
    Dalloz F; Maupoil V; Lecour S; Briot F; Rochette L
    Mol Cell Biochem; 1997 Dec; 177(1-2):193-200. PubMed ID: 9450662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxicity of nitric oxide in Fu5 rat hepatoma cells: evidence for co-operative action with hydrogen peroxide.
    Ioannidis I; de Groot H
    Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):341-5. PubMed ID: 8257422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed.
    de Mey C; Breithaupt K; Seibert-Grafe M; Belz GG
    Eur J Clin Pharmacol; 1994; 46(4):295-9. PubMed ID: 7957511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells.
    Yu SM; Cheng ZJ; Guh JH; Lee FY; Kuo SC
    Biochem J; 1995 Mar; 306 ( Pt 3)(Pt 3):787-92. PubMed ID: 7702575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation by nitric oxide of prostaglandin biosynthesis in the rat.
    Sautebin L; Ialenti A; Ianaro A; Di Rosa M
    Br J Pharmacol; 1995 Jan; 114(2):323-8. PubMed ID: 7533614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells.
    Heller R; Bussolino F; Calvino R; Ghigo D; Alessio P; Todde R; Fruttero R; Pescarmona G; Gasco A; Till U
    Agents Actions; 1993 Nov; 40(3-4):157-65. PubMed ID: 7517616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of the molsidomine metabolite SIN-1 on coronary arteries and peripheral vessels of sheep with special reference to tolerance and endothelium.
    Yousif MH; Yousif F; Thulesius O
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):769-73. PubMed ID: 1909561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.